StemCell Therapy

Peter DazeleyGetty Images

Fancy a tea break? No, we insist, really. Because a new study has linked drinking regular mugs of the stuff to living longer. So, whether you need to take a breather from a work deadline, or want to wind down with a book before bed, a cuppa will do more than help you feel calm.

The research, published in the journal Annals Of Internal Medicine, found that people who sip on at least two cups of black tea daily experienced boosted longevity. Scientists looked at the drinking habits of more than 500,000 participants and discovered that it reduced the risk of mortality by between nine per cent and 13 per cent over a decade.

While the impact may be impressive, the reasons why are still a little unclear. It is thought that the polyphenol content of tea might be responsible for improved heart health. One thing's for sure, the researchers concluded that whether you add milk or sugar to your brew, it didn't seem to make a difference.

The study also indicates that black tea - drunk by 89 per cent of participants - could be just as beneficial as green tea. The latter has long been linked to improved wellbeing, with research showing that it can help with everything from brain function to cardiovascular health.

It builds on previous investigations by scientists into the virtues of your tea break. A previous study suggested that drinking tea could improve brain structure, helping you become more organised and efficient. Meanwhile, other research indicated that it could reduce many risk factors for heart disease, including by lowering blood pressure. Hot stuff.

Talking of warming beverages, here's what experts want you to know about Starbucks' Pumpkin Spice Latte...

This content is imported from {embed-name}. You may be able to find the same content in another format, or you may be able to find more information, at their web site.

Excerpt from:
Drinking two cups of tea a day is linked to boosted longevity - Women's Health UK

The annual Longevity Project kicks off Friday, Sept. 2, with the first in a series of articles on the topic of cancer. The reporting series will touch on cancer prevalence, advancements in medicine, mental health impacts, access to care and more.

The Longevity Project is a weekslong effort by the Summit Daily News to educate our readers about what it takes to live a long, fulfilling life in the High Country.

The series of articles will be published on the first four Fridays in September followed by an event Sept. 29 at 10 Mile Music Hall in Frisco featuring speaker Scott Lindgren, an expedition kayaker who has a brain tumor.

We know cancer touches every part of a community in some way, so in conjunction with the public health reporting project, were asking readers to share their stories of survival or loss as it relates to a cancer diagnosis.

Stories can be submitted at SummitDaily.com/submit-longevity and will be shared in the Summit Daily as well as in the program guide for the Longevity Project event.

Excerpt from:
Share your story of loss or survival as part of The Longevity Project series on cancer - Summit Daily

Over the years, the asphalt industry has been working hard to improve the longevity of the pavements we drive on. We have acknowledged the fact that the right treatment, on the right pavement, at the right time is much more cost-effective than removing and replacing an asset once it's beyond repair. We as an industry know this, the smart asset owners know this, and yet many pavements are left to deteriorate while new roads and other needs take priority.

"Asset owners have more pavements in need of preservation than money to preserve them," John Hickey,executive director at the Asphalt Pavement Association of Oregon said. "Managers set short-term budgets in almost every sector and that has permeated the public infrastructure sector even though the considerations driving how we budget for infrastructure necessitate a long-term perspective. Even if pavement preservation budgets initially are sufficient, funding often gets diverted to what is perceived as more pressing needs. Maybe its a new pedestrian bridge or light rail system regardless of the benefit those new assets may confer, they are often paid for out of existing infrastructure funding without consideration for the long-term effects on the overall system. We tell our kids they cant get new things until they learn to take care of what they have, but we dont live by that rule when it comes to public infrastructure."

And the problem isn't getting any better.U.S. roads received aD gradein ASCE's 2021 Report Card, retaining the D they got back in 2017. Breaking down the nation's roads into four grading categories, 41.9 percent are categorized as good, 15.6 percent as fair, 22.6 percent as mediocre and 20.1 percent as poor.

So why has there been no improvement? The simple answer is perception.

"Pavements show deterioration relatively slowly and it is easy to think they will last another season or two, which will give us time to figure out a funding," Hickey says. "The obvious problem is that the newly added infrastructure often costs more than we initially estimate and it also requires preservation and maintenance. Pavement managers are in a constant battle advocating for pavement preservation funding in a system where the people who allocate the dollars want to show constituents something shiny and new."

In order to make impactful change on the lifespan of our pavements, the industry needs to continually push a long-term preservation strategy and deploy a "fix it first" mentality when it comes to our roadways.

According to the National Center for Pavement Preservation, there are nearly 4 million miles of paved public roads in the United States, valued at $1.75 trillion. The roads and other pavements in America are a huge investment and are vital for moving people and goods in an efficient manner. Yet we let them fall into a state of disrepair.

Unfortunately, there is very little new funding in the Infrastructure Investment & Jobs Act (IIJA) specifically dedicated to repair and no new requirements on highway monies for prioritizing repair on roads and bridges. Overall the law doubled down on the practice of giving states immense flexibility with the bulk of their money and then hoping that they use that flexibility to prioritize repair.

States should consider a "fix it first" approach to using these funds.

"In 2017, the Oregon Legislature passed a major infrastructure funding bill that had multiple funding mechanisms to adequately pay for, among other things, improving bridge seismic resiliency and preserving pavements," Hickey says. "But, the final bill included earmark projects in primarily urban areas, which are notorious for taking a long time and being expensive."

As inflation continues to be a challenge for State DOTs, it they truly want to do more with less money, preservation is the answer.

If inflation wasnt bad enough, as pavement conditions decline, pavement preservation costs increase. So what are the solutions to keep up with continual pavement decline?

In Oregon, it's Thinlays.

"Thinlays are the most beneficial pavement preservation technique," Hickey says. "Added structure and improved smoothness are probably the two Thinlay benefits that are most relevant since we need pavements to support increased loading and improved smoothness can result in a significant reduction in greenhouse gas emissions from vehicles."

Thin asphalt overlays are a reliable way to restore smoothness and drivability to an aging pavement, while correcting distresses and even adding structural value in some instances.Typically, a thin asphalt overlay is a surface mix of 1.5 inches or less placed on a well prepared surface. The pavement being overlaid may be milled or unmilled, but it should not show signs of structural distress requiring a more extensive rehabilitation.

The decision to apply a thin overlay to an existing pavement surface should be made only after a careful evaluation of the pavement condition and the elimination of the need to perform a structural rehabilitation. You also need careful consideration of an entire pavement maintenance program, otherwise costs can creep up on you.

"The primary challenge in implementing a Thinlay pavement preservation program is the fact that they often have a higher initial cost and it is hard for pavement managers to overcome the budgeting hurdles described above," Hickey says. "Marion County in Oregon is an example of an agency that has had success implementing a Thinlay program, which has improved pavement conditions and set the County up for lower pavement preservation costs over the long-term."

One of the biggest benefits of asphalt pavements is their ability to be built upon, year over year, while maintaining structural strength.

"Perpetual Pavement" is the name coined to describe a layered, flexible pavement design and construction concept. Application of the concept produces a deep-strength asphalt pavement that can resist structural fatigue distress for a long time (at least 50 years) and, thus, results in a long-lived pavement. These long-lasting structural bases can be economically maintained by replacing just the surface, never needing total removal and replacement.

Perpetual pavements are designed to develop distresses from the top-down, rather than from the bottom-up. This preserves the integrity of the bottom layers of the pavement structure, and confines damage to the top layer where it can be easily managed without requiring full-depth repairs or major rehabilitation. In fact, we now know that asphalt pavements can be designed toneverdevelop bottom-up fatigue-related distress, regardless of how many loads are applied to the pavement, and how heavy those loads may be.

By confining damage to the top layer of the pavement, maintenance and rehabilitation costs over the life of a perpetual pavement are significantly reduced. And given the fact that the lower layers of pavement are preserved, the structural life of a perpetual pavement is on the order of 50 years or more, rather than the 20-year life expectancy that has traditionally been the standard.

The cost savings and increased life expectancy are huge benefits that smaller agencies and local governments cant afford to ignore. Both high-volume highways and interstates and low-volume county roads and city streets can reap the benefits of perpetual pavement too, even if those structures were not originally designed or built to perpetual specifications. Perpetual pavement can, in fact, be achieved by increasing pavement thickness one inch of asphalt at a time.

For local agencies with limited budgets, that extra inch of asphalt will pay for itself many times over by reducing long-term maintenance costs and doubling the life expectancy of the road itself.

Here is the original post:
How the Asphalt Industry Can Improve Pavement Longevity - For Construction Pros

Many pastors, particularly newbies, have a noble aspiration to stay long term in a church. I think it is safe to say that most of us know the value of serving long-term in one place. It gives us the privilege of journeying with people as they travel through different seasons of lifesomething not possible with short-sprint ministries. It also provides the opportunity to bring about deep and long-lasting change in a church.

For many of us, long-term ministry is a dream that turns into a nightmare.

Then the harsh realities of pastoral ministry hit us like a speeding freight train. We find ourselves looking for an exit; for greener pastures somewhere else.

Too often, people enter church ministry with blissful naivety; without recognising and weighing up the cost of staying in a church long term. Its like people who love the thrill of climbing Mt Everest but who fail to understand how much it costs to get to the top. If we want to last the distance, we need to take a hard and honest look at how much it will cost us and ask if we are prepared to pay that price. So what is the cost we need to be aware of? Here are three parts to it:

We all love speed. We are always looking for things to happen faster and faster. Faster internet. Faster fast food. Faster computers. Faster microwave food. Things need to move faster. Top Guns Maverick sums it up: I feel the need; the need for speed.

If we plan to serve in one church long term, then we have to sacrifice our need for speed. Changing and growing a church can be very very very slow and by slow I mean more than a few months or even a year. Sometimes it takes decades.

Changing and growing a church can be very very very slow. Sometimes it takes decades.

I remember speaking to a young pastor who was excited about his new church. Six months into it he was still excited. After two years he was ready to pull the plug.

Of course, some churches seem to change faster than a speeding bullet. But many others move at snails pacepainfully slow for speed-lovers. But why should we be surprised? Churches are not like speed boats that can do 180-degree spins at the drop of a hat. They are like ocean liners that take a long time to change course.

Churches come with traditions, practices, values and customs that have accumulated over yearsmaybe even centuries! It will take time to decipher them, let alone change them. To think we can change the church overnight (or even in a year or two) is crazy. Just earning peoples trust will take longer than that: As the saying goes, It is hard to earn a persons trust. But it can be easily lost overnight.

However, if slowness is a problem for us, we need to remember that it isnt for God. He was prepared to wait until Abram and Sarai were old before miraculously providing their first child. He was prepared to wait 400 years before bringing Israel out of Egypt (Gen 15:12-16). He was prepared to wait 80 years before using Moses for that job. God has his own timing.

Yet things are usually happening in the meantime. When things are slow, we need to recognise that God is still at work, changing people every minute of the day in quiet and subtle ways. Even in the most hardened of churches, the Spirit of God will use the Word to bring about Christ-like transformation. It is worth remembering the book of Ruth: as the whole nation of Israel was going down the toilet (see Judges), God was at work in a country village, bringing together a Ruth and Boaz, through whom David and his greater Heir would come to the rescue.

Who likes to fail? Success is something we pursue and celebrate. We put our successful leaders on pedestals and urge everyone to be like them.

Unfortunately, church ministry often sings to a similar tune. We pick successful pastors to be guest speakers at our church growth conferences, clinging to the worldy hope that we might be able to copy their formula. Notice that one of the key questions in strategic planning is, What does success look like?

Now, Im not against being successful, and I certainly dont want to be someone who cuts down tall poppies. It is important to plan for success. But we need to remember that success is something God gives us. He may use our planning and effort, but he does not depend on them. Success is up to God, not us (see 1Cor 3:5-9).

If we are serious about long-term ministry, we need to know and be prepared for a string of failures.

If we are serious about long-term ministry, we need to know and be prepared for a string of failures. There will be people we will fail. Many sermons will go down like lead balloons. We will make wrong (if notbad) decisions that will hurt people. We will fail to give some people the attention they need. People will complain about our boring meetings. We may fail to disciple people; fail to raise up leaders; fail to visit the sick; fail to evangelise our community; fail to raise money; fail to find extra staff. We might lose our cool or say the wrong thing that causes people to leave the church.

Failure is part and parcel of any long-term ministry. This is not an excuse for failure. It is simply to recognise that we will not always get it right. Indeed, many times we will get it wrong.

That might demoralise us. A string of failures and mistakes might make us want to pack our bags and move on. But if we are serious about staying, we will have to pick ourselves up and keep pushing on. We also need to remember that while no one loves to be a failure, God loves failures and died for them. We need to remember that our failures should not define us, nor do they need to be the end of the world (though some moral failures will disqualify us from ministry).

Yet, what ultimately defines us is not what we fail to do for God but what God has successfully done for us. He loved us, not because we were so good, but quite the opposite. Remember Pauls words in 2 Cor 11:16-33. As the super-apostles paraded their super credentials, Paul paraded his failures and weaknesses. As he reminds us, it is when we are weak that Gods grace is more than sufficient. 2 Cor 12:9.

Our natural instinct for self-preservation makes us want to avoid pain at all costs. But if we are serious about long-term ministry, we will need to be prepared for hurt that will come time and time again. Many of us have a dreamy view of ministry; that it is all fun and games. If we talk about suffering, we think of it as the sort of suffering we have to endure to get fit.

But long-term pastoral ministry is not for the faint-hearted. People will complain and criticise and often unfairly. They will complain about your preaching, your leadership, your decisions, your dress code, your manner, your pay, and your attitude. People you have depended on will turn against you and stab you in the back. Church leaders will gang up on you because you are trying to do the right thing. Although you are trying to serve the church, some people will think you are leading them to deaththink about Moses. Of course, we are not Moses, but many of us probably have an idea of how he must have felt.

But again, why should we expect anything different? Although the church is Gods holy people, they are still a bunch of ratbag kids who need to grow up to become like Christ. In his graciousness, God has given us a part in this. But as any parent will tell you, raising children can be painful. In Galatians 4:19, Paul even likens his efforts to the pains a mother goes through in giving birth to a baby. This is the pain he feels until Christ is fully formed in the church. It is hard enough to endure birth pangs for an hour or two. Imagine 20 years of them!

If we are serious about long-term ministry, we need to be prepared for the years of such pain. Are we prepared to pay this cost? We need to be if we are serious about long-term ministry.

And yet, if we are serious, Gods grace and power will prove to be more than sufficient to sustain us to the very end. As Paul wraps his ministry and passes the baton to Timothy, he encourages him with these words:

For this reason I remind you to fan into flame the gift of God, which is in you through the laying on of my hands. For the Spirit God gave us does not make us timid, but gives us power, love and self-discipline. So do not be ashamed of the testimony about our Lord or of me his prisoner. Rather, join with me in suffering for the gospel, by the power of God.(2 Timothy 1:6-8, NIV)

Read this article:
Longevity: Playing the Long Game in Ministry - The Gospel Coalition

New Delhi: Widely considered one of the most significant figures of the second half of the 20th century, Mikhail Gorbachev, the last president of the Soviet Union passed. Gorbachev, credited with ending the Cold Wat without any bloodshed lived till the age of an astounding 91 years, even though was suffering from long and a serious illness that has always been shrouded in mysteries. Earlier this year Gorbachev, whose biggest contribution was to provide Russians with freedom of speech and multi-party democracy, had been hospitalized for an unknown kidney ailment, which media reports said was dialysis treatment but was refuted by the Tass. The cause of his death has not been announced yet.

A few years back, Australian media had also said he was suffering from severe diabetes, a claim not verified.

Secrets of Gorbachevs longevity

According to the Tass, the Nobel Prize winner will be buried in Moscow's Novodevichy cemetery, next to his wife Raisa.

Unabashed love for family and celebration of bondsGorbachev was married to Raisa for 46 years before she died of leukemia in 1999. In the volumes of his memoirs, which he had dedicated to her, Gorbachev had mentioned being heartbroken by her death. He loved traveling and used to take short breaks with his family to rejuvenate and recuperate from the stressful work times.Gorbachev's memoirs also feature pictures from the various family holidays taken in and outside Russia.

Love of Music: A great stress buster

In the dark night, I know that you, my love, are awake, sitting by the crib you're secretly wiping away a tear; How I love your deep gentle eyes, how I want to press my lips to yours," he sang for an interview to the BBC way back in 2013.

Unfailing sense of humor

Gorbachev was also known for his humorous takes on serious politics. According to various journalists who interviewed him, especially after he left office, Gorbachev used to take a dig at himself quite often. "Look, now I need three legs to get around!" He told BBCs Steve Rosenberg in Moscow after he started using a stick to walk around. "What happened to the USSR was my drama. And a drama for everyone who lived in the Soviet Union," he chuckled as he spoke about the fall of the USSR.

Link:
Know 3 longevity secrets of the last USSR President Mikhail Gorbachev who died at the ripe age of 91 - Times Now

Longevity is an important aspect and factor when it comes to evaluating all-time athletes in any sport. The ability to maintain one's greatness is important, as it shows that someone can be a winning player over a period of time rather than having a short peak and a worse overall career.

There are a lot of legends playing professional sports currently that have elite longevity. Tom Brady is still a good quarterback in the NFL, Serena Williams has recently moved on to the third round of the 2022 US Open after upsetting her opponent, while LeBron James is still a superstar in the NBA. We are witnessing greatness all around.

Recently, Philadelphia 76ers guard Tyrese Maxey offered some praise for LeBron James, Serena Williams, and Tom Brady and their longevity. He jokingly asked about what is "in the water" that those three athletes are drinking, and it's clear that Maxey is amazed atwhat those legendary stars have been able to accomplish.

What is in the water Bron, Serena, and TB12 drinking!? At this point Im just curious!

There is no doubt that those athletes have had long and productive careers and will retire as legends of their respective sports. Most NBA fans know that LeBron James' longevity in the sport is absolutely unprecedented. Once, former player Eddie Johnson pointed out that players such as Magic Johnson and Larry Bird were "no longer relevant" by the time they were LeBron James' age, and noted that this "lets you know how great" James actually is.

Its amazing how LeBron at almost 37 is still being ripped for struggling, when he has an AD in his prime and not living up to expectations. Magic, Bird, Duncan, Hakeem, and Jordan were no longer relevant at 37. That lets you know how great LBJ is. Keep it moving."

Hopefully, we see LeBron James have another good year with the Los Angeles Lakers next year. While the team missed out on the playoffs this past season, they have revamped their roster, and perhaps that will lead to a different outcome for the next year.

As for Tyrese Maxey, he will likely be focused on trying to win a championship with the Philadelphia 76ers. Many expect him to become the third star of the franchise behind James Harden and Joel Embiid, and he definitely has the talent to do so.

Continue reading here:
Tyrese Maxey Lauds LeBron James, Serena Williams, And Tom Brady For Their Longevity: "What Is In The Water Bron, Serena, And TB12...

Auckland: New Zealand left-arm seamer Mitchell McClenaghan is worried of senior players not being valued much by the New Zealand Cricket (NZC) upon reaching a certain age.

McClenaghans fears come after pace all-rounder Colin de Grandhomme announced his retirement from international cricket on Wednesday.

A veteran of 29 Tests, 45 ODIs and 41 T20Is who played an integral hand in the success of New Zealand in recent times, de Grandhomme was selected by the Adelaide Strikers ahead of season 12 of the Big Bash League (BBL) through an inaugural overseas draft. De Grandhomme, 36, follows in the footsteps of Kiwi left-arm pace bowler Trent Boult, who too was granted a release from his central contract by NZC.

Also Read: Hope Next Year He is Not Worried About the Orange Cap

I think once youre at a certain age, youre not really valued at New Zealand Cricket. I feel like there should be some reward for longevity in this game, particularly with the way the contracts are set up with NZC.

Youre on a year-by-year contract so theres actually no security at all. Youre not an employee like you are with New Zealand Rugby, where youre on a longer-term contract where you dont need to look over your shoulder and youre on good money, said McClenaghan on SENZ Breakfast show.

McClenaghan, who played 48 ODIs and 29 T20Is for New Zealand, feels that lack of security in NZC contracts was why de Grandhomme announced his retirement from international cricket after bagging a BBL deal with Strikers.

You could lose your job tomorrow so all your security is out the window, so I can understand why Colin waited until he had a job to go to before kicking it in. I think in his mind he probably thought hed have four or five Tests left at a max and then that (would) probably be taken towards the end of his career. Thats just the nature of being a contractor unfortunately for NZC and obviously for New Zealand cricketers as well.

ASIA CUP 2022:FULL COVERAGE|SCHEDULE|RESULTS

New Zealand will be next seen in action in a three-match ODI series in Australia starting from September 6.

Get the latest Cricket News, Schedule and Cricket Live Scores here

Read more here:
'There Should be Some Reward for Longevity in This Game'-Kiwi Pacer Wants Change In Central Contracts - News18

On Friday, August 26, the CSUF Kinesiology and Public Health departments honored 33 esteemed emeriti by unveiling a portrait wall in the KHS building.

Bill Beam, kinesiology professor and chair emeritus (1983-2015) was instrumental in planning the event, bringing together alumni, current and former faculty, community members, college leadership, and, of course, the emeriti and their families.

Many notable CSUF emeriti were present for this event whose individual contributions include authoring world-class books on diving, receiving national recognition for research in veterans health and employee education for the U.S. Department of Veterans Affairs, and breaking the Chicago Cubs 108-year curse.

What a great way to honor our early leadersthe movers and shakers who brought us where we are, said Michele Wood, chair of public health. Public health started as a track in kinesiology. We are now working to establish a mental health and well-being scholarship, and re-envisioning HPRI into an entity that focuses on health equity and resilience. As a department, we are engaged, we are vibrant, we are productive, and we are mentoring future leaders.

Among the phrases that come to mind when one is honoring the people whose work, in this case, teaching, research, and service as well as their collegiality, have paved the way for those who have followed, is to say that we stand on the shoulders of giants,' said Steve Walk, chair and professor of kinesiology. While this phrase is apt, one also considers the often-used image of the tree, in our case the orange tree seen in our campus seal, for embodying longevity and wisdom, bearing the fruit that supports generations to come, establishing roots that ensure health, solidity, and longevity, and recording in its very core the successes and challenges of the past. And lets be honest, for a long time, physical education struggled for a security of place in higher education, strove to overcome cultural stereotypes, intellectual prejudices and associated hierarchies, and in its work to become kinesiology, almost came apart at the seams on some campuses. Not so much at Cal State Fullerton. Your work to build the department was done in the context of these challenges, and its successes are a testament to your shared beliefs and commitment to working collegially to bring them about.

Continue reading here:
Kinesiology and Public Health Emeriti Honored | CSUF News - CSUF News

Two experts from Cleveland Clinic explain how a new cell-based gene therapy is helping patients with certain types of leukemia, with research into potential wider applications continues.

As World Leukemia Day approaches on 4 September, experts from global health system Cleveland Clinic are working on new immunotherapy treatments for blood cancers such as leukemia, expanding treatment options and bringing hope to patients for whom other treatments have failed.

Leukemia is a group of cancers characterized by rapid, uncontrolled growth of abnormal blood cells called leukemia cells. It can occur in children and adults and according to the World Cancer Research Fund International, it is the 13th most prevalent cancer globally.

According to Jan Joseph Melenhorst, PhD, a translational immunologist who is Director of Cleveland Clinics recently established Cell Therapy and Immuno-Engineering Program, chimeric antigen receptor (CAR) T-cell therapy is profoundly changing the treatment landscape, bringing the promise of durable remission for many patients with blood cancers such as leukemia.

Dr-Jan Joseph-Melenhorst

CAR T-cell therapy is a specialized treatment using a patients own T-cells a type of white blood cell that forms part of the immune system.

The T-cells are extracted and genetically modified so that they can recognize and destroy cancer cells, before being multiplied and infused back into the bloodstream, explains Dr. Melenhorst, who is also Vice Chair of the Center for Immunotherapy and Precision Immuno-Oncology at Cleveland Clinic.

He added that while CAR T-cell therapy has brought new hope for many patients, there are currently several challenges to overcome in administering the treatment.

In particular, it may be more expensive than other therapies. Additionally, it has potentially serious side effects.

This limits access to treatment as the therapy needs to be administered on an inpatient basis at a specialized facility where the side effects can be managed. We are working with Clevelands Case Western Reserve University and other parties and collaborating with various manufacturers to address issues such as accessibility, safety, and costs, he says.

Dr. Melenhorst and his team are also aiming to improve the efficacy of existing CAR T-cell therapies while developing new versions for a wide range of blood and other cancers.

Their colleague, Craig Sauter, MD, is a hematologist and Director of Blood and Marrow Transplant at the Cleveland Clinic who has been using CAR T-cell therapy to successfully treat patients with leukemia and other blood cancers where other treatments have failed.

The standard of care in initial therapy for many acute leukemia patients remains cytotoxic chemotherapy, with the aim of achieving remission. In cases where first-line chemotherapy or other treatments have failed, however, CAR T-cells provide another potential treatment option for patients with B-cell acute lymphoblastic leukemia. In the FDA-approved indications, it has proved much more effective than the previous standard, which was a further round of chemotherapy, he says.

The U.S. Food and Drug Administration (FDA) has approved commercial CAR T-cell products for several types of blood cancers including acute lymphocytic leukemia (ALL) in patients who have been resistant to other treatments or whose cancer has returned after a period of remission. Clinical trials are also underway at institutions including Cleveland Clinic for CAR T-cells to treat acute myeloid leukemia (AML).

ALL and AML are two of the four main types of leukemia. The disease is classified as acute or chronic based on how rapidly the disease spreads in the body, and as myeloid or lymphocytic depending on whether the leukemia cells arise from myeloid cells, which develop in bone marrow, or from lymphoid cells, which are related to the immune system.

Dr. Craig Sauter

Explaining how the procedure works in practice,

Dr. Sauter says the first step is to extract the patients lymphocytes and insert an inactive virus that delivers new genetic instructions to the T-cells to start producing chimeric antigen receptors targeting proteins that live on the malignant cells.

Researchers take a small batch of these newly altered CAR T-cells and induce them to grow and multiply until there are enough to effectively target cancer cells.

The CAR T-cells are frozen and stored until the patient is ready to receive them. To prepare for the infusion, the patient receives a mild form of chemotherapy to prevent the immune system from rejecting the CAR T-cells.

According to Dr. Sauter, most people need to stay in the hospital for one to two weeks so their response to the treatment can be monitored and any side effects treated. The two most common side effects of CAR T-cell therapies are cytokine release syndrome (CRS) and neurological problems such as headaches, confusion, or difficulty speaking during the treatment period.

Dr. Sauter points out CAR T-cell therapy is in its early phase, but he is cautiously optimistic about its potential. In future, as a result of further research and carefully conducted studies, there may be an opportunity to identify high-risk groups who may benefit from having CAR T-cell therapy over chemotherapy in earlier lines of treatment, he says. The possibility of its application being extended to treat other forms of cancer is also very exciting.

Cleveland Clinic is a nonprofit multispecialty academic medical center that integrates clinical and hospital care with research and education. Located in Cleveland, Ohio, it was founded in 1921 by four renowned physicians with a vision of providing outstanding patient care based upon the principles of cooperation, compassion and innovation. Cleveland Clinic has pioneered many medical breakthroughs, including coronary artery bypass surgery and the first face transplant in the United States.

Read the original:
Hope For Leukemia Patients, Where Other Treatments Have Failed - Longevity LIVE - Longevity LIVE

The researchers evaluated changes in DNA methylation and discovered that hibernation slows biological aging.

The big brown bat, which is the most common type of bat in the United States, has an incredibly long lifespan of up to 19 years. One of the secrets to this bats exceptional lifespan has been discovered by a recent study headed by scientists at the University of Maryland: hibernation.

Hibernation has allowed bats, and presumably other animals, to stay in northerly or very southerly regions where theres no food in the winter, said the studys senior author, UMD Biology Professor Gerald Wilkinson. Hibernators tend to live much longer than migrators. We knew that, but we didnt know if we would detect changes in epigenetic age due to hibernation.

The scientists discovered that a big brown bats epigenetic clocka biological marker of agingis extended by three-quarters of a year by hibernating for one winter. Scientists from McMaster University and the University of Waterloo, both in Ontario, Canada, were also involved in the research, which was publishedin the Proceedings of the Royal Society B.

Big brown bats can live up to 19 years. Credit: Brock and Sherri Fenton

Small tissue samples from the wings of 20 big brown bats (Eptesicus fuscus) collected across two periodswinter when they hibernated and the summer when they were activewere analyzed. The bats were housed in a research colony at McMaster University and ranged in age from less than a year to a little more than ten years.

The samples were then compared with samples obtained from the same animal during active and hibernating phases to determine changes in DNA methylation, a biological process connected to gene regulation. They revealed that certain sites in the bats genome had changes in DNA methylation, and these sites seemed to be impacting metabolism during hibernation.

Its pretty clear that the sites that decrease methylation in the winter are the ones that appear to be having an active effect, Wilkinson said. Many of the genes that are nearest to them are known to be involved in regulating metabolism, so they presumably keep metabolism down.

Some of these genes were identified as longevity genes by Wilkinson and colleagues in a previous study. According to Wilkinson, there is considerable overlap between hibernation genes and longevity genes, highlighting the relationship between hibernating and longer lifespans.

The previous study also created the first epigenetic clock for bats, which can reliably predict the age of any bat in the wild. This clock was used in the current study, allowing the researchers to show that hibernation decreases a bats epigenetic age when compared to a non-hibernating animal of the same age.

Studies like this one help to explain why bats have longer lives than would be expected for a small mammal the size of a mouse. They do, however, raise new questions.

We still dont have a very good understanding of why some bats can live a really long time and other ones dont, Wilkinson said. Weve shown that the ones that live a really long time all share the ability to hibernate or to go into torpor frequently. That seems to be a corollary, but its not sufficient because hibernating rodents dont live 20 years.

Wilkinson said he is planning a follow-up study to compare epigenetic aging in big brown bats in Canada, where they hibernate, with the same species in Florida, where they do not hibernate. In doing so, Wilkinson hopes to get an even clearer picture of the role that hibernation plays in prolonging lifespans.

Reference: Big brown bats experience slower epigenetic ageing during hibernation by Isabel R. Sullivan, Danielle M. Adams, Lucas J. S. Greville, Paul A. Faure and Gerald S. Wilkinson, 10 August 2022, Proceedings of the Royal Society B Biological Sciences.DOI: 10.1098/rspb.2022.0635

The study was funded by the American Society of Mammalogists, Sigma Xi, the University of Maryland, and the Natural Sciences and Engineering Research Council of Canada.

Read the original here:
Researchers Discover the Secret to a Small Mammals Exceptional Lifespan - SciTechDaily

Reparative techniques are vital in endodontics, andconservative measureshelp preserve the vitality of teeth and ensuring they are in good health [1,2]. Mineral trioxide aggregate(MTA) is a biocompatible compound that has found widespread usage in clinical endodontic therapy because of its low cytotoxicity and high biocompatibility and ability to stimulate new dentin development. It has been the material of paramount importance since its introduction in the 1900s [3]. Uses of MTAinclude conservative management of root fractures, perforation repair [4], pulp capping agent [5], apexification [6], retrograde filling material in apical microsurgeries [7], and revascularization measures as a coronal barrier[2]. The above procedures involve close contact with the body fluids and vital tissues, favoring physical alterations and chemical/biological communications with the material [8].

Various properties of MTA, such as physical, chemical, and biological, have been explored for extended periods, leading to discoveries of its efficient substitutes. However, improvisations are still needed to arrive at an ideal composition of the constituents of the cement. The development of a model, unflawed restorative material is still long due. To achieve thisit should possess the following characteristic properties: sealing ability, dimensional [9] and color stability [10], radio-opacity [11], insolubility when in contact with body fluids, and ability to flow with easy insertion. It should also possess biological and chemical properties such as alkaline pH, calcium (Ca) ion release, bioactivity, cell attachment, and biocompatibility[12]. Mineral trioxide aggregate owns most of the mentioned ideal properties but lacks a few, primarily color and consistency which require the most improvisations[13]. Therefore, materials with newer innovations have been launched commercially to overcome these shortcomings. This review intends to highlight the properties of MTAwith their limitations and to arrive at the developments in innovative Ca silicate-based cements (CSCs).

The main emphasis should be on the clinical facet of these CSCs, as the site of placement directly influences and determines materialproperties[14]. Mineral trioxide aggregateis a dynamic, active material as its application and placement result in constant contact of the cement with tissues and fluids. It persists for years after its insertion[15]. Its mechanism comprises Ca hydroxide leaching out of the hydrated MTA, thereby highlighting the bioactivity of MTA, which relates to the calcium ion(Ca2+) release. Placement of MTAis usually required at the site where there is a presence of blood that contaminates it, affecting the structure of the set material and reducing the Ca2+ release[6,16]. The principal limitations of MTA include a delayed setting time, lack of good handling features, and the disadvantage of discoloration.

Also, the contact of MTAwith blood can alter the color of the material andinterferes with radiopacity over time[17]. Moisture drastically affects the time of setting and the material solubility. Excessive water results in increased solubility and setting time of MTA. During the setting process of MTA, it chemically interacts with tissues making the environment alkaline by releasing Ca2+ ions, which are linked to the development of portlandite (calcium hydroxide) by tricalcium silicate (C3S) and dicalcium silicate (C2S)[18].

In vitro studies done with MTAAngelus and ProRoot MTArevealed Ca2+ ion discharge andalkalization of the environment when the material was submerged in water. The release of Ca2+ ions was detected by von Kossa staining of subcutaneous tissues of rats[19]. These properties lead to mineralization on the surface of the set MTAin pulpotomy procedures. This is proven by studies where hard tissue was formed apically in a dog's teeth which were seen along with the sealing ability in cases of furcation perforation[20].

In an in vivo study by Han et al., the odontogenic potential of osteostatin (OST) and the combined effect with bioceramic materials on human dental pulp stem cells (hDPCs) were investigated, and it was discovered that the combination of MTAand OSThad a synergistic odontogenic differentiation of hDPCs when compared to MTAalone[21]. Micro-CT research demonstrated that OSTwith ProRoot MTAgroups formed more mineralized dentin bridges[22].

During dental operations, the most significant property of observation is color. Tooth discoloration damages the tooth's aesthetic appearance. The complex response between filling materials and coronal dentine of the pulp chamber, which modifies the crowns appearance, is a significant cause of tooth discoloration.

Initially, when developed, MTAhad a grey color owing to the presence of tetra Ca aluminoferrite, making it unsuitable for its application on anterior teeth. Therefore, this led to the establishment of white MTA which is devoid of iron to prevent the discoloration of the tooth. On the contrary, many studies have proven the alteration in color even with white MTA[23]. The composition of white MTAincludes C2S and C3S silicate with 20% of bismuth oxide. According to reports, the amount of bismuth oxide added to MTA to increase its radio-opacity was only 8.4% in the set material compared to 21.6% in the unset material [8]. When reduction of bismuth oxide occurs along with its contact with the tooth structure, it alters the color of the cement and the color of the adjacent tooth structure. The cause of color change has been identified and attributed to the loss of stability of the bismuth oxide molecules, which occurs as they come in close contact with a potent oxidizing agent[24]. Hence, it is suggested that if the radiopacifier agent is changed, it can help prevent the discoloration of the tooth. Two materials have been lab tested to replace bismuth oxide, namely zirconium oxide and Ca tungstate. However, large amounts are necessary to match the radiopacity ofbismuth oxide. Adding such large amounts can negatively impact the chemical and physical properties of the dental material[25]. Newer CSCs such as Biodentine and Bioceramic (BC) sealer, and MTA high plasticity (HP) can alter the radiopacifier agent into Ca tungstate or zirconium oxide.These constituents caused no alteration in color[26]. The second substitute is the addition of 5% zinc oxide (ZnO) to MTAas this ZnO converts bismuth oxide into bismite, a product that helps prevent the change of color[10].

There is a difference in opinion regarding the consistency of MTA. The ratio of powder to water is essential as increasing the quantity of water reduces radiopacity. The particle size is vital here as the newer advances in silicate types of cement have been developed using nanoparticles of Ca silicate (CS). The BCsealer and biosealer containing nanoparticles of CSwith the addition of a polymer help in easy handling and givean ideal material consistency. Adding propylene glycol to MTAcaused no interference in its biological properties. Propylene glycol was tested using different ratios for chemical and physical properties in which 20% propylene glycol was mixed with 80% distilled H2O,which led to efficient handling of MTA, pH, enhanced Ca release, and flowability. However, it caused slight alterations in setting time[27]. Few studies have proven that propylene glycol caused improved adhesion of MTA.

The advances which lead to enhanced flow ability comprise MTA HP, MTA Flow, Biodentine (Septodont, Saint-Maur-des-Fosss, France),and ones having ceramic complexes incorporated with Biodentine, EndoSequence (Brasseler, Savannah, GA, USA), and BioAggregate (Verio Dental Co. Ltd., Vancouver, Canada).

In 2009, Biodentine, a Ca silicate-based product, was introduced. Zirconium oxide is used instead of bismuth oxide in Biodentine. Zirconium oxide is a bioinert substance with good mechanical qualities & corrosion resistance. Dettwiler et al. 2016 observed this closely in an experiment [28]. Biodentine had a minor discoloration, higher solubility than MTA, and a significantly faster setting time. In as little as 12 minutes, Biodentine can begin to block blood components, becoming denser and packed as it sets. As a result, erythrocyte penetration is reduced, resulting in less tooth discoloration during the pulpotomy operation. Because it comprises more powder with a water-reducing agent and less porosity, the Biodentine material significantly impacts various factors such as absorption, strength, and density[29]. Biodentine and zinc oxide-eugenolcement (IRM) had the lowest level or degree of porosity and the least amount of tooth discoloration, according to Camilleri et al. in 2013[14].

Endosequence root repair material (ERRM), is available as a premixed putty with uniform consistency and easier handling and application. According to the manufacturer, the setting begins with the presence of moisture in the dentinal tubules. When pulp cells were exposed to ERRMor ProRoot MTA, survival and proliferation were identical, suggesting that it could be a good choice for pulp capping treatments[30].

BioAggregate (BA)contains monobasic Ca phosphate, amorphous silicon dioxide, and tantalum pentoxide for radiopacity. And due to its Ca phosphate content,it is classified as a biphasic material (one that contains two cementitious ingredients)[31]. It is more acid resistant than MTA, has a longer-lasting strengthening effect on weaker teeth, and has a lower risk of discoloration[31]. In the treatment of immature teeth, it has demonstrated similar results as MTA.

The main composition of MTAis CS. Bioactivity is one characteristic feature of Ca silicate-based types of cement[27]. Newer CS-based restorative types of cement have been launched to substitute bismuth oxide like Biodentine, Neo MTAPlus (Avalon Biomed Inc.Bradenton, FL, USA), and MTARepair HP (Angelus, Londrina, PR, Brazil). Others include MTAFillapex (Angelus, Londrina, PR, Brazil), Neo MTAPlus, iRoot SP (Innovative BioCreamix Inc, Vancouver, BC, Canada), and TotalFill BC (Davis Schottlander & Davis Ltd. Letchworth, Herts, UK) sealer.

The MTAFillapex cement comes in a paste-paste form which comprises salicylate and natural resin, infused silica nanoparticles, MTA, and Ca tungstate which acts as radiopacifier.There is a newly introduced C2S silicate-based system with a powder-gel formulation named Neo MTA, a remarkable restorative and endodontic cement that can be used with various proportions of powder gel ratios. The composition of iRoot SPis zirconium oxide, CS, Ca phosphate, Ca hydroxide, and thickening agents, which are commercially accessible and is used as a root canal filling material. On the other hand, EndoSequence BC sealer and TotalFill BC sealer comprises zirconium oxide, CS, monobasic Caphosphate, Ca hydroxide, and thickening agents. This latter cement is advantageous as it sets in the presence of dentin moisture and hence was used as canal filling material.

A study on iRoot SPendodontic cement advocated the absence of cytotoxicity to fibroblasts when tested in rats[32]. Alternative research by Zoufan et al., checked the cell compatibility of iRoot SPcement at two stages: after the cement was freshly mixed, and after the cement had been set[33]. It was found that this cement had a greater induction capacity of osteoblastic differentiation and decreased inflammatory response with the periodontal ligament cells compared to Sealapex[34].

The MTAand iRoot SPtypes of cement have been proven to induce differentiation in osteoblastic cells in the tooth germ. The iRoot SPsignificantly showed its antibacterial activity against Enterococcus faecalis[35]. Zhu et al. found evidence of the ability of BioAggregate cement to promote cell adhesion to each other, migration, and fixation of human dental pulp cells, thus proving its cytocompatibility[36].

Bioceramic endodontic cement-like Endosequence BC sealerhas displayed promoting superior cell viability than AHPlus sealer and also offered an increased level of biocompatibility when compared with newly handled AHPlus and MTAFillapex,when freshly mixed and after the setting. Bioceramic sealer has shown satisfactory adhesion to fibroblasts[37]. Upon contact with the biological solution, discharge of Ca and development of the Ca phosphate phase was seen. Antibacterial activity against biofilm formed on dentin was greater when Endosequence BC sealer was used along with 5% sodium hypochlorite than the irrigation solution alone[38]. In a study using confocal laser microscopy, Wang et al. concluded that in 30 days, a BioCeramic sealer could eliminate 45% of E. faecalis from the dentinal tubules, indicating the antibacterial action of theBioceramic sealer lasted even after the setting of the material [39]. Total fill BioCeramic sealer is identical to Endosequence BC sealer. The only difference is that the former promotes extensively higher proliferation of cells compared to AHPlus and MTA Fillapex.The structure of cells embedded on Total Fill BioCeramic Sealer and AHPlus showed similar physiognomies, along with the assembly of the extracellular matrix. In contrast, limited fixation of cells was seen on discs of MTAFillapex, with decreased number of cells on the material surface[40].

The MTA Angelus, MTA HP, and Neo MTA P presented viability of cells and a higher degree of cellular proliferation along with adhesion. Using HDPCs, greater viability was seen with MTAplus compared to MTAFillapex and Fillcanal; increased phosphates activity was observed with MTAPlus[41,42]. No cytotoxic effect was seen with Neo MTAPlus, MTAAngelus, and experimental C3S silicate-based cement with tantalum oxide (TSC/Ta205). According to the alizarin red assay, the three materials were proven to induce the formation of mineralized nodules; on the other hand, NEOproduced a considerable quantity of mineralized nodules compared to MTAand TSC[43]. Following subcutaneous implantation in rats, histological analysis established that MTA HPshowed similar biomineralization and biocompatibility potentials to MTA Angelus[43]. The MTAAngelus and MTAPlus showed no presence of cytotoxicity and induced mineralized nodule formation. When PCR was used, the authors concluded that when HDCPs were exposed to extract the two types of cement, it increased the expression of osteogenic markers of the cell[44].

According to Petrovic et al., materials based on CSand hydroxyapatite (HA-CS) showed a superior grade of biocompatibility compared to MTAAngelus [45]. Also, improved outcomes were seen for CS and HA-CS when subcutaneous implants were placed in rats. In the assessment of the biocompatibility of three Ca silicate-based types of cement, which include Bioroot BC sealer (BR), Endoseal MTA(ES) & Nanoceramic sealer (NCS), along with human periodontal ligaments stem cells (hPDLSCs), BRand NCSshowed superior cytocompatibility as compared to ES[46]. The BCsealer was proficient in hindering the release of immunoreactive calcitonin gene-related peptide (iCGRP) from trigeminal ganglion neurons and excellent biocompatibility, thereby reducing the symptomatology level after extravasation of the cement in ongoing treatment[47].

In a study by Almedia et al., a comparison of physiochemical and biological properties of already mixed Ca silicate-based endo sealers with routinely used root canal (RC) filling materials by thoroughly revising lab investigations [48]. Calcium silicate-based endodontic sealers followthe ISO 6876:2012 standard for most physicochemical properties, except solubility. The target sealers depicted commendatory biological traits in comparison to conventional sealers. Despite failing to test the target premixed Ca silicate-based sealers in long-term experimental clinical trials, they presented with good physicochemical and biological traits in vitro.

Visit link:
A Breakthrough in the Era of Calcium Silicate-Based Cements: A Critical Review - Cureus

Source: Northwestern University

Cells are the building blocks of tissue, and tissues are the basic unit of function in the body. Generally, groups of cells make and secrete their own support structures, called extra-cellular matrix. This matrix, or scaffold, does more than just support the cells; it also acts as a relay station for various signaling molecules. Thus, cells receive messages from many sources that become available from the local environment. Each signal can start a chain of responses that determine what happens to the cell. By understanding how individual cells respond to signals, interact with their environment, and organize into tissues and organisms, researchers have been able to manipulate these processes to mend damaged tissues or even create new ones.

The process often begins with building a scaffold from a wide set of possible sources, from proteins to plastics. Once scaffolds are created, cells with or without a cocktail of growth factors can be introduced. If the environment is right, a tissue develops. In some cases, the cells, scaffolds, and growth factors are all mixed together at once, allowing the tissue to self-assemble.

Another method to create new tissue uses an existing scaffold. The cells of a donor organ are stripped and the remaining collagen scaffold is used to grow new tissue. This process has been used to bioengineer heart, liver, lung, and kidney tissue. This approach holds great promise for using scaffolding from human tissue discarded during surgery and combining it with a patients own cells to make customized organs that would not be rejected by the immune system.

View original post here:
Tissue Engineering and Regenerative Medicine - National Institute of ...

OPTIMAL Pain & Regenerative Medicine focuses on treating patients through restorative and pain management solutions. We offer state of the art biologic treatments that have changed the way medicine is practiced today. Our practice specializes in the treatment of neck and back pain, arthritis, neuropathy, diseases, headaches, joint and soft-tissue injuries and sports related injuries.

Dr. Scott Berlin and Dr. Michael Phillips of OPTIMAL Pain & Regenerative Medicine strive to be at the forefront in providing cutting edge pain management and regenerative medicine options to the Dallas-Ft. Worth metroplex. As board certified anesthesiologists, their collective expertise includes a full range of innovative treatment options. No matter what your stage of life, OPTIMAL delivers comprehensive, current and most importantly, compassionate medical care.

To date, it is estimated that over 116 million American adults are affected by some degree of chronic pain. Pain management is important for patients who are suffering from acute, chronic and cancer pain. Pain management includes injection/interventional therapy, implantable therapies, physical therapy,medication managementand other suitable treatment options.

Regenerative medicine offers a solution to patients who have conditions that seem beyond repair. Regenerative medicine is a process of replacing the bodys owns cells, tissues or organs to restore normal function. OPTIMAL specializes in minimally invasive bone marrow aspirate concentrate (BMAC), a stem cell therapy for back pain, as well as platelet rich plasma therapy (PRP) for joints or soft tissue injuries.

To get to learn more about our practice please review our physician profiles and patient education.

Go here to read the rest:
Pain Management & Regenerative Medicine Specialists DFW

The project for the development of the International Stem Cell and Regenerative Medicine Research and Therapeutic Center in Egypt is moving forward.

Recently, the North African countrys Ministry of Defense awarded a management and supervision consultancy services contract for the project. The contract was awarded to Hill International an American construction consulting firm that provides program, project, and construction management services.

International Stem Cell and Regenerative Medicine Research and Therapeutic Center in Egypt will feature three components categorized as facilities. These will be the animal welfare facility, the bioreactor facility, and the research facility. Moreover, center staff will have the opportunity of using the new facilities. The staff will have the liberty of conducting basic and preclinical clinical trials with stem cells.

The healthcare project represents the latest effort to enrich the countrys healthcare sector. It aims to leverage the therapeutic potential of stems to develop. The development of stem cells will contribute to a major advance in regenerative medicine.Moreover, it would be a great opportunity to not just promote health and welfare in Egypt, but to the whole world as well.

Also Read:Contracts signed for UC Development projects in NAC, Egypt

The International Stem Cell and Regenerative Medicine Research and Therapeutic Center in Egypt will work in cooperation and together with industrial, non-governmental, academic as well as governmental institutions.

The CEO of Hill International spoke about the project. Raouf Ghali affirtmed that the firm will make use of its expertise to ensure the project is realized as planned. Moreover, the CEO added that the company is proud of the projects progress as it will be of great impact on the country.

Hill International boasts over 3,200 professionals in approximately 100 offices worldwide. Impressively, the ENgineering New-Record magazine ranks the firm as one of the largest construction management firms.

If you need more information on this project. Current status, project team contacts etc. Please contact us

(Note this is a premium service)

Read more from the original source:
International Stem Cell and Regenerative Medicine Research and Therapeutic Center in Egypt - Construction Review

Media Advisory

Wednesday, August 31, 2022

At the National Institutes of Health, a surgical team successfully implanted a patch of tissue made from patient cells with the goal of treating advanced dry age-related macular degeneration (AMD), also known as geographic atrophy. Dry AMD is a leading cause of vision loss among older Americans and currently has no treatment.

The patient received the therapy as part of a clinical trial that is the first in the United States to use replacement tissues from patient-derived induced pluripotent stem (iPS) cells. The surgery was performed by Amir H. Kashani, M.D., Ph.D., associate professor of ophthalmology, Wilmer Eye Institute, Johns Hopkins School of Medicine with assistance by Shilpa Kodati, M.D., staff clinician, NEI. The procedure was performed at the NIH Clinical Center in Bethesda, Maryland, under a phase 1/2a clinical trial to determine the therapys safety.

This iPS cell derived therapy was developed by the Ocular and Stem Cell Translational Research Section team led by Kapil Bharti, Ph.D., senior investigator at the National Eye Institute (NEI), part of NIH, in collaboration with FUJIFILM Cellular Dynamics Inc., and Opsis Therapeutics, based in Madison, Wisconsin. Safety and efficacy of this cell therapy was tested by the NEI preclinical team. Clinical-grade manufacturing of this cell therapy was performed at the Center for Cellular Engineering, Department of Transfusion Medicine, Clinical Center, NIH.

This surgery is the culmination of 10 years of research and development at the NEI. In the NIH lab, the patients blood cells were converted to iPS cells, which can become almost any type of cell in the body. In this case, they were programmed to become retinal pigment epithelial (RPE) cells, the type of cell that degenerates in the advanced forms of dry AMD. RPE cells nourish and support light-sensing photoreceptors in the retina. In AMD, the loss of RPE leads to the loss of photoreceptors, which causes vision loss. This work was supported by the NIH Common Fund and NEI Intramural funding.

Kapil Bharti, Ph.D., senior investigator, Ocular and Stem Cell Translational Research Section, NEI

Brian Brooks, M.D., Ph.D., chief, Ophthalmic Genetics and Visual Function Branch, NEI

To schedule interviews with Drs. Bharti and Brooks, contact NEI at neinews@nei.nih.gov

NIH launches first U.S. clinical trial of patient-derived stem cell therapy to replace and repair dying cells in retina (News release)

NIH researchers rescue photoreceptors, prevent blindness in animal models of retinal degeneration (News release)

Autologous Transplantation of Induced Pluripotent Stem Cell-Derived Retinal Pigment Epithelium for Geographic Atrophy Associated with Age-Related Macular Degeneration (Clinical trial information)

About the NEI: NEI leads the federal governments efforts to eliminate vision loss and improve quality of life through vision researchdriving innovation, fostering collaboration, expanding the vision workforce, and educating the public and key stakeholders. NEI supports basic and clinical science programs to develop sight-saving treatments and to broaden opportunities for people with vision impairment. For more information, visit https://www.nei.nih.gov.

About the National Institutes of Health (NIH):NIH, the nation's medical research agency, includes 27 Institutes and Centers and is a component of the U.S. Department of Health and Human Services. NIH is the primary federal agency conducting and supporting basic, clinical, and translational medical research, and is investigating the causes, treatments, and cures for both common and rare diseases. For more information about NIH and its programs, visit http://www.nih.gov.

NIHTurning Discovery Into Health

###

Excerpt from:
First U.S. patient receives autologous stem cell therapy to treat dry AMD - National Institutes of Health (.gov)

Global regenerative medicine market was valued at USD 27.29 Billion in 2020. It is expected to increase at a compound annual rate (CAGR of 11.27%) between 2021 and 2027. Tissue Engineering is the segment expected to see the greatest growth in the Global Regenerative Medicine Market. Biomaterials currently hold the largest market share in global regenerative medicine.

Regenerative medicine has the potential to treat chronic, incurable diseases such as Alzheimers disease, Parkinsons disease, diabetes, and other conditions. The Alliance for Regenerative Medicine estimates that around 1,028 clinical trials in regenerative medicine are currently underway. In 2018, regenerative medicine was funded with a total of USD 13.3 billion in global financing. The forecast period will see a significant increase in investment by market leaders in research and development of regenerative medicines.

Driving Factors

Growing prevalence of chronic diseases, genetic disorders, and cancer

Over the past few decades, the prevalence and incidence of chronic diseases like CVD, cancer and diabetes has increased dramatically around the world. Diabetes and obesity can lead to an increase in the number and complexity of wounds like infections, ulcerations (leg and foot ulcers), as well as surgical wounds. These will need treatment and may result in exorbitant medical costs.

Ask For PDF Sample Report Here: https://market.us/report/regenerative-medicine-market/request-sample/

Restraining Factors

High cost of cell and gene therapies

The cell and gene therapies represent significant medical and scientific advancements for patients with serious and terminal illnesses. These therapies are changing the way diseases are treated and could even be cured. Injectable therapies will enable doctors and other medical professionals to infuse cells/genes through injectable methods, thereby avoiding multiple surgeries and the need for a number of drugs. Although these therapies can be life-saving and more effective than traditional treatments, demand is lower than anticipated. This is due to the high cost of these therapies as well as difficulties in obtaining coverage and reimbursements for them.

Market Key Trends

Recent development

Do you have any questions? Consult about the report at: https://market.us/report/regenerative-medicine-market/#inquiry

Key Companies

Segmentation

Type

Application

Frequently Asked Questions About This Report

Explore our related report:

About Market.us

Market.US (Powered by Prudour Private Limited) specializes in in-depth market research and analysis and has been proving its mettle as a consulting and customized market research company, apart from being a much sought-after syndicated market research report providing firm.

Contact Details:

Global Business Development Team Market.us

Address: 420 Lexington Avenue, Suite 300 New York City, NY 10170, United States

Phone: +1 718 618 4351 (International), Phone: +91 78878 22626 (Asia)

Email: [emailprotected]

Read the original post:
Regenerative Medicine Market to Garner Bursting Revenues [+USD 27.29 Billion] with Top Growing Companies During 2022-2029 - eTurboNews | eTN

Immusoft is heading into the clinic with what it claims is the first engineered B cell gene therapy cleared for in-human study, the company announced Thursday.

The Seattle-based company reported it has received clearance from the FDA to initiate a Phase I study assessing ISP-001 for the treatment of Mucopolysaccharidosis type I. MPS I is a rare lysosomal storage disorder characterized by an abnormal build-up of glycosaminoglycans in the body. Immusoft aims to improve treatment of MPS 1, also known as Hurler Syndrome, with its Immune System Programming platform that uses B cells as re-dosable biofactories for therapeutic protein delivery.

Immusoft stated its platform has been designed to circumvent both immunogenicity associated with virus-delivered gene therapy, as well as chemotherapy preconditioning associated with stem cell-mediated gene therapy. Additionally, the ISP platform has been designed to enable durable therapeutic delivery and the potential to re-dose patients if necessary.

The FDA has granted ISP-001 Orphan Drug designation and Rare Pediatric Disease designation for MPS 1. The Phase I study is expected to launch later this year, the company announced.

Sean Ainsworth, chairman and CEO of Immusoft, expressed excitement over the IND clearance. He called it a huge achievement for the company and a historic moment in the field of cell and gene therapies. Current adeno-associated virus therapies and lentiviral therapies have some safety concerns. The delivery mechanism in those therapies can trigger an immune response in patients, which can limit efficacy. Stem cell treatments also have some drawbacks in some patients.

Ainsworth told BioSpacethat the companys B cell approach has been designed to overcome some of the issues that were seen in other gene therapy modalities. Building on advances made in other cell therapeutic approaches such as CAR-T therapies, Ainsworth said the company is pioneering a gene therapy approach that allows for a durable therapeutic and the potential to re-dose patients.

Our engineered B cell approach is a completely novel modality that opens potential new avenues for treating intractable diseases. Having our lead program cleared to proceed into the clinic - the first B cell approach in the clinic - broadens the potential for our platform and pipeline as we advance other programs to first-in-human studies, Ainsworth said in an email this morning.

B Cell-Focused Competition

Immusoft isnt the only company focused on the development of B cell therapies. Others include Be Biopharma and Walking Fish Therapeutics.

Paul Orchard, a professor in the division of pediatric bone marrow transplantation at the University of Minnesota Medical Center, noted that a non-viral delivery method such as ISP-001 holds promise for the treatment of some diseases, such as MPS I. He said there is a clear need for new treatments for MPS I, as current options are not curative and significant disease-related morbidity still exists.

Although there is no cure for MPS I, there are several treatment options, including hematopoietic stem cell transplant and BioMarins Aldurazyme (laronidase), an enzyme replacement therapy. However, enzyme replacement therapies require frequent infusions, which affect quality of life. Immusoft hopes its therapeutic will mitigate the need for frequent dosing and improve patient outcomes.

Other companies developing therapies for MPS I include Orchard Therapeutics and REGENXBIO.

Beyond MPS I, Immusoft has partnered with the California Institute for Regenerative Medicine on the development of a therapy for MPS II, a carbohydrate metabolism disorder.

Read the rest here:
Immusoft Takes First-Ever Engineered B Cell Therapy into Clinic - BioSpace

Photo courtesy of Mayo

With the promise of regenerative medicine comes the risk of widening health care disparities. Sometimes the newest discoveries, such as regenerative interventions, are out of reach for people in diverse ethnic or socioeconomic groups or they may not understand or trust new options for healing.

Mayo Clinicis trying to overcome those barriers by launching community outreach and a bioethics study aimed at improving access to regenerative medicine among underserved groups.

Regenerative medicine sometimes could look like a science fiction movie. It is important to learn from the community about how things could be better explained to them or how we can erase any doubts that they have about what we do, says Jorge Mallea, M.D., a pulmonologist at Mayo Clinic in Florida. Listening to their concerns, and explaining what we know, the things still we dont have solutions for, and what we are trying to accomplish could improve understanding and engagement.

Regenerative medicine is an emerging field of practice that is shifting the focus of health care from fighting disease to rebuilding health, with an emphasis on repairing, replacing or restoring diseased cells and tissues. Mayo ClinicsCenter for Regenerative Medicineis at the vanguard of this movement, supporting the concept of regeneration for all. Dr. Mallea chairs the centers Equity, Inclusion and Diversity Advisory Committee.

More diverse clinical trials

To ensure that regenerative therapies go beyond selected or priority groups, Mayo Clinic is expanding the recruitment for clinical trials to include more diversity in race, age and socioeconomic status. For example, a dermatology study in Rochester is exploring how certain regenerative interventions might affect ethnic groups with different skin tones.

We want to learn more about diverse groups to ensure the therapies we apply would work for people of different genders, races and genetics, says Dr. Mallea. Its important to have representation from diverse groups. We could learn in our clinical trials that certain groups need different doses or distinct ways of applying the interventions.

In other research,Zubin Master, Ph.D., a bioethicist in Mayo ClinicsBiomedical Ethics Research Program, is leading a bioethics study that seeks to understand possible economic, social and ethnic barriers toplatelet-rich plasma platelets spun from a persons own blood and containing growth factors as an orthobiologic treatment for kneeosteoarthritis. Platelet-rich plasma is a new regenerative intervention that shows healing potential. However, the Food and Drug Administration has not yet approved it. Therefore, patients must pay out of pocket for it.

Mohamed Addani, aMayo Clinic Graduate School of Biomedical Sciencesstudent within Dr. Masters team, will interview patients across Mayo Clinic who choose platelet-rich plasma as an intervention for knee osteoarthritis and those who opt instead for standard care. The team will compare those responses to a more demographically diverse group of patients whove made similar care choices at Detroit Medical Center. Researchers will examine race, ethnicity, socioeconomic and demographic variables, beliefs, attitudes, and understanding of regenerative medicine.

This study will provide the first scientifically based data on whether health disparities exist among patients seeking next-generation regenerative interventions such as platelet-rich plasma, says Dr. Master. The results will give us the unique opportunity to identify factors that are creating barriers to regenerative care and proactively address ways to overcome them.

The project seeks to improve access and make regenerative medicine more equitable among diverse and underserved groups.

Showcasing the cool stuff

Attracting a more diverse pool of regenerative medicine scientists and practitioners is another strategy to boost inclusivity. Mayo Clinic is taking regenerative medicine on the road to high schools and colleges near its destination locations in Arizona, Florida and Minnesota, showcasing what Dr. Mallea describes as the cool stuff in research and development. The hope is that it might inspire students, particularly those from underrepresented and disadvantaged communities, to consider a career in regenerative medicine.

We are sharing examples of our research, such as bioprinting of organs and developing new medicines from living organisms like cells to fight different diseases and cancers, says Dr. Mallea. We hope to plant a seed in their minds that regenerative medicine holds promise not only as a future therapy, but also a future career.

In addition, Mayo is using the Community Scientist Program to open its doors to scientists from the community who want to learn more. This program pairs community scientists with regenerative medicine researchers. Mayo hopes these strategies will improve the interaction and understanding needed to ensure access to new regenerative therapies as they are introduced in the practice.

Envision yourself working for a global leader in an industry fueled by innovation and growth. Mayo Clinic has opportunities for you. Join us at Floridas No. 1 hospital by visiting https://jobs.mayoclinic.org/. For more information on health care topics please visit Mayo Clinic Jacksonville at mayoclinic.org.

See original here:
Addressing Diversity Barriers to Regenerative Medicine Free Press of Jacksonville - Jacksonville Free Press

LEXINGTON, Mass.--(BUSINESS WIRE)--Frequency Therapeutics, Inc. (Nasdaq: FREQ), a clinical-stage regenerative medicine company focused on developing therapeutics to activate a persons innate potential to restore function, today announced that members of its management team will participate in investor and medical conferences later this month.

A live webcast of the presentations from the HC Wainwright and Baird conferences can be accessed on the Investors & Media section of Frequencys website. A replay will be posted following the event.

About Frequency Therapeutics

Frequency Therapeutics is leading a new category in regenerative medicine that aims to restore human function first in hearing loss and then in multiple sclerosis by developing therapeutics that activate a persons innate regenerative potential within the body through the activation of progenitor cells. Frequencys hearing research focuses on cochlear restoration and auditory repair, and its lead asset, FX-322, is a small-molecule product candidate that is the first to show statistically significant and clinically meaningful hearing improvements in clinical trials for sensorineural hearing loss. Frequency is also advancing a pre-clinical program for remyelination in multiple sclerosis.

Headquartered in Lexington, Mass., Frequency has an ex-U.S. license and collaboration agreement with Astellas Pharma Inc. for FX-322, as well as additional collaboration and licensing agreements with academic and nonprofit research organizations including Massachusetts Eye and Ear, Mass General Brigham, the Massachusetts Institute of Technology, and the Scripps Research Institute.

For more information, visit http://www.frequencytx.com and follow Frequency on Twitter @Frequencytx.

Read more:
Frequency Therapeutics to Participate in September Investor and Medical Conferences - Business Wire

VIKEN, Sweden, Aug. 31, 2022 /PRNewswire/ -- TikoMed, a biopharmaceutical company focused on harnessing the medical potential of the body's ability to self-repair and regenerate, today announced the publication in Frontiers in Phamacology of peer-reviewed research supporting the unique broad spectrum mechanism of action of TikoMed's ILB neuroprotective drug platform. In multiple preclinical and clinical studies across a variety of neuroinflammation-driven diseases, the low molecular weight dextran sulfate compound both mobilized and modulated naturally occurring tissue repair mechanisms and restored cellular homeostasis and function by releasing heparin-binding growth factors. TikoMed believes this approach to enhancing the body's self-repair and regeneration capabilities has the potential to transform current cell and gene therapy paradigms.

"These studies show that ILB releases, re-distributes and modulates the bioactivity of endogeneous heparin-binding growth factors that target disease compromised nervous tissues to initiate a cascade of transcriptional, metabolic and immunological effects that play a key role in controlling glutamate toxicity, normalising tissue bioenergetics, and resolving inflammation to improve tissue function. ILB's unique mechanism of action supports the potential to treat various acute and chronic neurodegenerative disease, including sTBI and ALS," said Ann Logan, Scientific Director at Axolotl Consulting and, Professor of Regenerative Medicine at the University of Warwick.

In summary, the studies provided evidence that ILB has a profound therapeutic effect on molecular and cellular dysfunctions causing neurodegenerative diseases. Gene expression analysis demonstrated substantial similarities in the functional dysregulation induced by severe traumatic brain injury (sTBI) and various human neurodegenerative conditions including ALS. Changes in gene expression following ILB treatment supported a cascading beneficial effect of ILB on growth factor activation resulting in the observed therapeutic effect. The transcriptional signature after ILB treatment is relevant to cell survival, inflammation, glutamate signalling, metabolism and synaptogenesis, and is consistent with the activation of neuroprotective growth factors. The ability of ILB to elevate circulating levels of heparin-binding growth factors in animal models and humans also supports its neuroprotective and regenerative effects in vivo.

Story continues

"ILB is currently being in development both as a therapeutic and as an enabling technology for advanced therapies, and this peer-reviewed research indicates even wider potential. We have initiated development programs for Amyotrophic Lateral Sclerosis (ALS), Traumatic Brain Injury (TBI) and islet cell transplantation and will now consider broader use across a wider range of diseases," said Anders Kristensson, CEO of TikoMed.

Contact: info@tikomed.com or +46 42 23 84 40

Media:

International: Richard Hayhurst richard@rhapr.eu or +44 7711 821527

Nordics: Ola Bjorkman ola.bjorkman@letemknow.se or +46 70 245 7497

This information was brought to you by Cision http://news.cision.com

https://news.cision.com/tikomed/r/tikomed-s-ilb--mobilizes-and-modulates-key-growth-factors-that-trigger-a-cascade-of-neuroprotective-,c3623306

SOURCE Tikomed

Go here to see the original:
TikoMed's ILB mobilizes and modulates key growth factors that trigger a cascade of neuroprotective mechanisms able to target all...